Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant.

Published

Journal Article

Pertussis, or whooping cough, has recently reemerged as a major public health threat despite high levels of vaccination. The development of a novel pertussis vaccine, especially an intranasal (i.n.) vaccine is undoubtedly necessary, and mucosal adjuvants have been explored to enhance the immune response. In the present study, bacterium-like particles (BLPs) were adopted as a mucosal adjuvant for an i.n. pertussis vaccine and evaluated on the ability to induce serum and mucosal antibodies as well as potency against i.n. challenge in mice. Groups with or without aluminum adjuvant were also evaluated through both i.n. and intraperitoneal inoculations. Vaccination with BLPs via the i.n. route led to rapid IgG and IgA production and provided strong protection against inflammation induced by infection. The results support an i.n. pertussis vaccine with BLPs adjuvant as a promising candidate to elicit protective immunity against whooping cough.

Full Text

Duke Authors

Cited Authors

  • Shi, W; Kou, Y; Jiang, H; Gao, F; Kong, W; Su, W; Xu, F; Jiang, C

Published Date

  • June 2018

Published In

Volume / Issue

  • 198 /

Start / End Page

  • 26 - 32

PubMed ID

  • 29601940

Pubmed Central ID

  • 29601940

Electronic International Standard Serial Number (EISSN)

  • 1879-0542

Digital Object Identifier (DOI)

  • 10.1016/j.imlet.2018.03.012

Language

  • eng

Conference Location

  • Netherlands